Drug Trial News

RSS

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

In global clinical trials, patients with advanced metastatic lung cancer who were treated with a targeted immunotherapy drug lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published today in the journal The Lancet.

15 Mar 2016

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing.

15 Mar 2016

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

15 Mar 2016

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer.

11 Mar 2016

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according to results from a clinical trial.

11 Mar 2016

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.

11 Mar 2016

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Eli Lilly and Company announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab in a Phase 3 clinical trial. Detailed results of the UNCOVER-2 study were presented during the American Academy of Dermatology Annual Meeting taking place March 4-8 in Washington, D.C.

8 Mar 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology 2016 Annual Meeting in Los Angeles. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids.

7 Mar 2016

Drug combination improves glucose control in Type 2 diabetes patients

A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, is associated with weight loss.

2 Mar 2016

Scientists start clinical trial to test new prostate cancer vaccine

Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.

1 Mar 2016

Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).

27 Feb 2016

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

27 Feb 2016

PharmaMar begins PM184 Phase II trial in advanced breast cancer patients

PharmaMar has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be conducted in 10 European clinical centres and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.

26 Feb 2016

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study.

26 Feb 2016

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).

25 Feb 2016

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV.

25 Feb 2016

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I.

25 Feb 2016

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of immunological data from the Company's clinical trials of SB-728-T, a ZFP Therapeutic designed to provide functional control of HIV.

25 Feb 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.

24 Feb 2016

Drug Trial News

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

Anticancer drug restores hearing in neurofibromatosis patients

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

Drug combination improves glucose control in Type 2 diabetes patients

Scientists start clinical trial to test new prostate cancer vaccine

Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

New drug shows promise against Huntington's disease

PharmaMar begins PM184 Phase II trial in advanced breast cancer patients

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News